机构：[1]Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Lymphoma, Peking University Cancer Hospital and Institute, Beijing, China,[2]Department of Hematology and Oncology, Harbin Institute of Hematology and Oncology, Harbin, China,[3]Department of Hematology, West China Hospital Sichuan University, Chengdu, China,四川大学华西医院[4]Department of Hematology, Henan Cancer Hospital, Zhengzhou, China,河南省肿瘤医院[5]Department of Hematology, Jiangsu Province Hospital, Nanjing, China,江苏省人民医院[6]Department of Hematology, The First Affiliated Hospital of Zhejiang University, Hangzhou, China,浙江大学医学院附属第一医院[7]Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China,[8]Department of Hematology, Qilu Hospital Shandong University, Jinan, China,[9]Department of Lymphoma, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China,[10]Department of Hematology, Tongji Hospital Huazhong University of Science and Technology, Wuhan, China,华中科技大学同济医学院附属同济医院[11]Department of Hematology, The Affiliated Union Hospital of Fujian Medical University, Fuzhou, China,[12]Department of Medical Oncology, The Cancer Institute and Hospital Chinese Academy of Medical Sciences, Beijing, China,[13]Department of Lymphoma, Fujian Cancer Hospital, Fuzhou, China,[14]Department of Medical Oncology, Union Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology, Wuhan, China,华中科技大学同济医学院附属协和医院[15]Department of Hematology, Shanghai Rui Jin Hospital, Shanghai, China,[16]Department of Hematology, Anhui Provincial Cancer Hospital, Hefei, China,[17]Department of Hematology, The Hematology Institute and Hospital Chinese Academy of Medical Sciences, Tianjin, China,[18]Department of Hematology, The First Affiliated Hospital Guangzhou Medical University, Guangzhou, China,[19]Department of Medical Oncology, Sichuan Cancer Hospital, Chengdu, China,四川省肿瘤医院[20]Department of Hematology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China,河北医科大学第四医院[21]Department of Medical Oncology, Nanjing General Hospital of Nanjing Military Command, Nanjing, China,[22]Department of Hematology, The First Affiliated Hospital of Xiamen University, Xiamen, China,[23]Department of Lymphoma, Hunan Cancer Hospital, Changsha, China,[24]Department of Hematology, Xijing Hospital of Airforce Medical University, Xi’an, China,[25]Department of Lymphoma, The Affiliated Hospital of Qingdao University, Qingdao, China,[26]Department of Hematology, The First Bethune Hospital of Jilin University, Changchun, China,[27]Department of Hematology, Nanfang Hospital of Southern Medical University, Guangzhou, China,[28]Department of Hematology, Sichuan Academy of Medical Sciences and Sichuan Provincial People’s Hospital, Chengdu, China,四川省人民医院[29]Department of Lymphoma, Zhejiang Cancer Hospital, Hangzhou, China,浙江省肿瘤医院[30]Department of Hematology, The First Hospital of China Medical University, Shenyang, China,[31]Department of Hematology, The First Affiliated Hospital of Anhui Medical University, Anhui, China,[32]Department of Hematology, Zhongshan Hospital Fudan University, Shanghai, China,[33]Department of Lymphoma, Guangdong Provincial People’s Hospital, Guangzhou, China,[34]Department of Hematology, People’s Hospital of Xinjiang Uygur Autonomous Region, Urumchi, China,[35]Department of Lymphoma, The Fifth Medical Center of the People's Liberation Army (PLA) General Hospital, Beijing, China,[36]Department of Hematology, Shandong First Medical University Affiliated Provincial Hospital, Jinan, China,[37]Department of Hematology, Nanjing Drum Tower Hospital of Nanjing University Medical School, Nanjing, China,[38]Department of Hematology, Peking Union Medical College Hospital, Beijing, China,[39]Department of Hematology, Peking University Shenzhen Hospital, Shenzhen, China北京大学深圳医院深圳市康宁医院深圳医学信息中心
Chidamide has demonstrated significant clinical benefits for patients with relapsed/refractory (R/R) PTCL in previous studies. This multi-center observational study was aimed to evaluate the objective response rate (ORR), overall survival (OS), and safety of chidamide. From February 2015 to December 2017, 548 patients with R/R PTCL from 186 research centers in China were included in the study. Among the 261 patients treated with chidamide monotherapy, ORR was 58.6% and 55 patients (21.1%) achieved complete response (CR). Among the 287 patients receiving chidamide-containing combination therapies, ORR was 73.2% and 73 patients (25.4%) achieved CR. The median OS of all patients was 15.1 months. The median OS of patients receiving chidamide monotherapy and combination therapies was 433 and 463 days, respectively. These results demonstrate a significant survival advantage of chidamide treatments as compared with international historical records. Common adverse effects (AEs) were hematological toxicities. Most AEs in both monotherapy and combined treatments were grade 1-2. No unanticipated AEs occurred. In conclusion, chidamide-based therapy led to a favorable efficacy and survival benefit for R/R PTCL. Future studies should explore the potential advantage of chidamide treatment combined with chemotherapy.
第一作者机构：[1]Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Lymphoma, Peking University Cancer Hospital and Institute, Beijing, China,
共同第一作者：
通讯作者：
推荐引用方式(GB/T 7714)：
Weiping Liu,Donglu Zhao,Ting Liu,et al.A Multi-Center, Real-World Study of Chidamide for Patients With Relapsed or Refractory Peripheral T-Cell Lymphomas in China[J].FRONTIERS IN ONCOLOGY.2021,11:doi:10.3389/fonc.2021.750323.
APA：
Weiping Liu,Donglu Zhao,Ting Liu,Ting Niu,Yongping Song...&Jun Zhu.(2021).A Multi-Center, Real-World Study of Chidamide for Patients With Relapsed or Refractory Peripheral T-Cell Lymphomas in China.FRONTIERS IN ONCOLOGY,11,
MLA：
Weiping Liu,et al."A Multi-Center, Real-World Study of Chidamide for Patients With Relapsed or Refractory Peripheral T-Cell Lymphomas in China".FRONTIERS IN ONCOLOGY 11.(2021)
